TGF-β Signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells

American Journal of Pathology

Volumn 181, Issue 6, 2012, Pages 2202-2216

  Yin, Miao ^a   Soikkeli, Johanna ^a   Jahkola, Tiina ^b   Virolainen, Susanna ^a   Saksela, Olli ^b   Hölttä, Erkki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; AE BINDING PROTEIN 1; ANTINEOPLASTIC AGENT; BB 3103; BINDING PROTEIN; CATHEPSIN B; CATHEPSIN L; CATHEPSIN L INHIBITOR; COMPLEMENT FACTOR I; CYSTEINE PROTEINASE INHIBITOR; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; SEPRASE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL ACTIVATION; COCULTURE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; CATHEPSIN B; CATHEPSIN L; CELL LINE, TUMOR; CELL PROLIFERATION; EMBRYO, MAMMALIAN; FIBROBLASTS; FLUORESCENT DYES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; NEOPLASM INVASIVENESS; NEVUS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84869193514     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.08.027     Document Type: Article

References (92)

1. M.J. Bissell, D. Radisky Putting tumours in context Nat Rev Cancer 1 2001 46 54
2. M.M. Mueller, N.E. Fusenig Friends or foes: bipolar effects of the tumour stroma in cancer Nat Rev Cancer 4 2004 839 849
3. T.D. Tlsty, L.M. Coussens Tumor stroma and regulation of cancer development Annu Rev Pathol 1 2006 119 150
4. K. Polyak, I. Haviv, I.G. Campbell Co-evolution of tumor cells and their microenvironment Trends Genet 25 2009 30 38
5. N.A. Bhowmick, E.G. Neilson, H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature 432 2004 332 337
6. A. Orimo, R.A. Weinberg Stromal fibroblasts in cancer: a novel tumor-promoting cell type Cell Cycle 5 2006 1597 1601
7. R. Kalluri, M. Zeisberg Fibroblasts in cancer Nat Rev Cancer 6 2006 392 401
8. J. Villanueva, M. Herlyn Melanoma Encyclopedia of Life Sciences (ELS) 2009 John Wiley & Sons Ltd Chichester
9. J.F. Thompson, R.A. Scolyer, R.F. Kefford Cutaneous melanoma Lancet 365 2005 687 701
10. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
11. M.F. Berger, J.Z. Levin, K. Vijayendran, A. Sivachenko, X. Adiconis, J. Maguire, L.A. Johnson, J. Robinson, R.G. Verhaak, C. Sougnez, R.C. Onofrio, L. Ziaugra, K. Cibulskis, E. Laine, J. Barretina, W. Winckler, D.E. Fisher, G. Getz, M. Meyerson, D.B. Jaffe, S.B. Gabriel, E.S. Lander, R. Dummer, A. Gnirke, C. Nusbaum, L.A. Garraway Integrative analysis of the melanoma transcriptome Genome Res 20 2010 413 427
12. K.L. Scott, C. Nogueira, T.P. Heffernan, R. van Doorn, S. Dhakal, J.A. Hanna, C. Min, M. Jaskelioff, Y. Xiao, C.J. Wu, L.A. Cameron, S.R. Perry, R. Zeid, T. Feinberg, M. Kim, G. Vande Woude, S.R. Granter, M. Bosenberg, G.C. Chu, R.A. DePinho, D.L. Rimm, L. Chin Proinvasion metastasis drivers in early-stage melanoma are oncogenes Cancer Cell 20 2011 92 103
13. A.M. Alcala, K.T. Flaherty BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance Clin Cancer Res 18 2012 33 39
14. T.J. de Vries, P.H. Quax, M. Denijn, K.N. Verrijp, J.H. Verheijen, H.W. Verspaget, U.H. Weidle, D.J. Ruiter, G.N. van Muijen Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression Am J Pathol 144 1994 70 81
15. Z. Shi, M.S. Stack Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity Biochem J 407 2007 153 159
16. K. Kessenbrock, V. Plaks, Z. Werb Matrix metalloproteinases: regulators of the tumor microenvironment Cell 141 2010 52 67
17. S.D. Mason, J.A. Joyce Proteolytic networks in cancer Trends Cell Biol 21 2011 228 237
18. V. Turk, J. Kos, B. Turk Cysteine cathepsins (proteases): on the main stage of cancer Cancer Cell 5 2004 409 410
19. M.M. Mohamed, B.F. Sloane Cysteine cathepsins: multifunctional enzymes in cancer Nat Rev Cancer 6 2006 764 775
20. E. Frohlich Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target Cell Mol Life Sci 67 2010 3947 3960
21. M. Hsu, D.E. Elder, M. Herlyn The Wistar (WM) melanoma cell lines J.Ma.B. Palsson, Human Cell Culture 1999 Kluwer Academic Publishers London 259 274
22. A. Gorden, I. Osman, W. Gai, D. He, W. Huang, A. Davidson, A.N. Houghton, K. Busam, D. Polsky Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues Cancer Res 63 2003 3955 3957
23. Y. Fernandez, M. Verhaegen, T.P. Miller, J.L. Rush, P. Steiner, A.W. Opipari Jr, S.W. Lowe, M.S. Soengas Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications Cancer Res 65 2005 6294 6304
24. J. Soikkeli, P. Podlasz, M. Yin, P. Nummela, T. Jahkola, S. Virolainen, L. Krogerus, P. Heikkila, K. von Smitten, O. Saksela, E. Holtta Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth Am J Pathol 177 2010 387 403
25. K. Ravanko, K. Jarvinen, J. Helin, N. Kalkkinen, E. Holtta Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts Cancer Res 64 2004 8831 8838
26. D.A. Zajchowski, M.F. Bartholdi, Y. Gong, L. Webster, H.L. Liu, A. Munishkin, C. Beauheim, S. Harvey, S.P. Ethier, P.H. Johnson Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells Cancer Res 61 2001 5168 5178
27. A. Paasinen-Sohns, E. Kaariainen, M. Yin, K. Jarvinen, P. Nummela, E. Holtta Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase Int J Biochem Cell Biol 43 2011 441 454
28. S.E. Seton-Rogers, Y. Lu, L.M. Hines, M. Koundinya, J. LaBaer, S.K. Muthuswamy, J.S. Brugge Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells Proc Natl Acad Sci U S A 101 2004 1257 1262
29. S.E. Wang, I. Shin, F.Y. Wu, D.B. Friedman, C.L. Arteaga HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta Cancer Res 66 2006 9591 9600
30. M. Kielosto, P. Nummela, R. Katainen, V. Leaner, M.J. Birrer, E. Holtta Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun Cancer Res 64 2004 3772 3779
31. J. Soikkeli, M. Lukk, P. Nummela, S. Virolainen, T. Jahkola, R. Katainen, L. Harju, E. Ukkonen, O. Saksela, E. Holtta Systematic search for the best gene expression markers for melanoma micrometastasis detection J Pathol 213 2007 180 189
32. V.G. Tusher, R. Tibshirani, G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci U S A 98 2001 5116 5121
33. MAQC Consortium L. Shi, L.H. Reid, W.D. Jones, R. Shippy, J.A. Warrington The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nat Biotechnol 24 2006 1151 1161
34. P. Nummela, J. Lammi, J. Soikkeli, O. Saksela, P. Laakkonen, E. Hölttä Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells Am J Pathol 180 2012 1663 1674
35. E. Kaariainen, P. Nummela, J. Soikkeli, M. Yin, M. Lukk, T. Jahkola, S. Virolainen, A. Ora, E. Ukkonen, O. Saksela, E. Holtta Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion J Pathol 210 2006 181 191
36. A.A. Sinha, M.J. Wilson, D.F. Gleason, P.K. Reddy, M. Sameni, B.F. Sloane Immunohistochemical localization of cathepsin B in neoplastic human prostate Prostate 26 1995 171 178
37. E. Wandel, A. Raschke, G. Hildebrandt, J. Eberle, R. Dummer, U. Anderegg, A. Saalbach Fibroblasts enhance the invasive capacity of melanoma cells in vitro Arch Dermatol Res 293 2002 601 608
38. P. Eves, E. Katerinaki, C. Simpson, C. Layton, R. Dawson, G. Evans, S. Mac Neil Melanoma invasion in reconstructed human skin is influenced by skin cells: investigation of the role of proteolytic enzymes Clin Exp Metastasis 20 2003 685 700
39. L. Li, B. Dragulev, P. Zigrino, C. Mauch, J.W. Fox The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo Int J Cancer 125 2009 1796 1804
40. V. Lulevich, Y.P. Shih, S.H. Lo, G.Y. Liu Cell tracing dyes significantly change single cell mechanics J Phys Chem B 113 2009 6511 6519
41. N.D. Rawlings, A.J. Barrett, A. Bateman MEROPS: the database of proteolytic enzymes, their substrates and inhibitors Nucleic Acids Res 40 2012 D343 D350
42. B.E. Gould Rothberg, M.B. Bracken, D.L. Rimm Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis J Natl Cancer Inst 101 2009 452 474
43. A. Vaisanen, P. Kuvaja, M. Kallioinen, T. Turpeenniemi-Hujanen A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53 Hum Pathol 42 2011 1103 1111
44. A. Breslow Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma Ann Surg 172 1970 902 908
45. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd, A.C. Buzaid, A.J. Cochran, D.G. Coit, S. Ding, A.M. Eggermont, K.T. Flaherty, P.A. Gimotty, J.M. Kirkwood, K.M. McMasters, M.C. Mihm Jr, D.L. Morton, M.I. Ross, A.J. Sober, V.K. Sondak Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
46. A. Spatz, N. Stock, G. Batist, L.C. van Kempen The biology of melanoma prognostic factors Discov Med 10 2010 87 93
47. S.R. Alonso, P. Ortiz, M. Pollan, B. Perez-Gomez, L. Sanchez, M.J. Acuna, R. Pajares, F.J. Martinez-Tello, C.M. Hortelano, M.A. Piris, J.L. Rodriguez-Peralto Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study Am J Pathol 164 2004 193 203
48. A. Saghatelian, N. Jessani, A. Joseph, M. Humphrey, B.F. Cravatt Activity-based probes for the proteomic profiling of metalloproteases Proc Natl Acad Sci U S A 101 2004 10000 10005
49. J.F. Fisher, S. Mobashery Recent advances in MMP inhibitor design Cancer Metastasis Rev 25 2006 115 136
50. A.M. Szpaderska, A. Frankfater An intracellular form of cathepsin B contributes to invasiveness in cancer Cancer Res 61 2001 3493 3500
51. D.J. Buttle, M. Murata, C.G. Knight, A.J. Barrett CA074 methyl ester: a proinhibitor for intracellular cathepsin B Arch Biochem Biophys 299 1992 377 380
52. E. Frohlich, B. Schlagenhauff, M. Mohrle, E. Weber, C. Klessen, G. Rassner Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma Cancer 91 2001 972 982
53. J.A. Tuxhorn, G.E. Ayala, M.J. Smith, V.C. Smith, T.D. Dang, D.R. Rowley Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling Clin Cancer Res 8 2002 2912 2923
54. Y. Kojima, A. Acar, E.N. Eaton, K.T. Mellody, C. Scheel, I. Ben-Porath, T.T. Onder, Z.C. Wang, A.L. Richardson, R.A. Weinberg, A. Orimo Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts Proc Natl Acad Sci U S A 107 2010 20009 20014
55. M. Guo, P.A. Mathieu, B. Linebaugh, B.F. Sloane, J.J. Reiners Jr Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B J Biol Chem 277 2002 14829 14837
56. C.D. Andl, K.M. McCowan, G.L. Allison, A.K. Rustgi Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner Neoplasia 12 2010 485 498
57. T. Kanzaki, A. Olofsson, A. Moren, C. Wernstedt, U. Hellman, K. Miyazono, L. Claesson-Welsh, C.H. Heldin TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences Cell 61 1990 1051 1061
58. J.P. Annes, J.S. Munger, D.B. Rifkin Making sense of latent TGFbeta activation J Cell Sci 116 2003 217 224
59. K. Miyazono, A. Olofsson, P. Colosetti, C.H. Heldin A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1 EMBO J 10 1991 1091 1101
60. O. De Wever, M. Mareel Role of tissue stroma in cancer cell invasion J Pathol 200 2003 429 447
61. C. Gaggioli, S. Hooper, C. Hidalgo-Carcedo, R. Grosse, J.F. Marshall, K. Harrington, E. Sahai Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells Nat Cell Biol 9 2007 1392 1400
62. I. Cornil, D. Theodorescu, S. Man, M. Herlyn, J. Jambrosic, R.S. Kerbel Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression Proc Natl Acad Sci U S A 88 1991 6028 6032
63. I. Stamenkovic Matrix metalloproteinases in tumor invasion and metastasis Semin Cancer Biol 10 2000 415 433
64. L.M. Coussens, B. Fingleton, L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392
65. S. Jodele, L. Blavier, J.M. Yoon, Y.A. DeClerck Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression Cancer Metastasis Rev 25 2006 35 43
66. P. Basset, J.P. Bellocq, C. Wolf, I. Stoll, P. Hutin, J.M. Limacher, O.L. Podhajcer, M.P. Chenard, M.C. Rio, P. Chambon A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas Nature 348 1990 699 704
67. C.M. Overall, O. Kleifeld Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat Rev Cancer 6 2006 227 239
68. L.H. Palavalli, T.D. Prickett, J.R. Wunderlich, X. Wei, A.S. Burrell, P. Porter-Gill, S. Davis, C. Wang, J.C. Cronin, N.S. Agrawal, J.C. Lin, W. Westbroek, S. Hoogstraten-Miller, A.A. Molinolo, P. Fetsch, A.C. Filie, M.P. O'Connell, C.E. Banister, J.D. Howard, P. Buckhaults, A.T. Weeraratna, L.C. Brody, S.A. Rosenberg, Y. Samuels Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma Nat Genet 41 2009 518 520
69. N. Bilalovic, B. Sandstad, R. Golouh, J.M. Nesland, I. Selak, E.E. Torlakovic CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression Mod Pathol 17 2004 1251 1258
70. A.K. Witkiewicz, B. Freydin, I. Chervoneva, M. Potoczek, W. Rizzo, H. Rui, J.R. Brody, G.F. Schwartz, M.P. Lisanti Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence Cancer Biol Ther 10 2010 391 396
71. R. Dennhofer, P. Kurschat, P. Zigrino, A. Klose, A. Bosserhoff, G. van Muijen, T. Krieg, C. Mauch, N. Hunzelmann Invasion of melanoma cells into dermal connective tissue in vitro: evidence for an important role of cysteine proteases Int J Cancer 106 2003 316 323
72. V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel, C. Peters, D. Hanahan, J.A. Joyce Distinct roles for cysteine cathepsin genes in multistage tumorigenesis Genes Dev 20 2006 543 556
73. K.M. Bell-McGuinn, A.L. Garfall, M. Bogyo, D. Hanahan, J.A. Joyce Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer Cancer Res 67 2007 7378 7385
74. P. Matarrese, B. Ascione, L. Ciarlo, R. Vona, C. Leonetti, M. Scarsella, A.M. Mileo, C. Catricala, M.G. Paggi, W. Malorni Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study Mol Cancer 9 2010 207
75. J.M. Lankelma, D.M. Voorend, T. Barwari, J. Koetsveld, A.H. Van der Spek, A.P. De Porto, G. Van Rooijen, C.J. Van Noorden Cathepsin L, target in cancer treatment Life Sci 86 2010 225 233
76. R.W. Mason, S. Gal, M.M. Gottesman The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L Biochem J 248 1987 449 454
77. S. Roshy, B.F. Sloane, K. Moin Pericellular cathepsin B and malignant progression Cancer Metastasis Rev 22 2003 271 286
78. J. Reiser, B. Adair, T. Reinheckel Specialized roles for cysteine cathepsins in health and disease J Clin Invest 120 2010 3421 3431
79. V. Turk, V. Stoka, O. Vasiljeva, M. Renko, T. Sun, B. Turk, D. Turk Cysteine cathepsins: from structure, function and regulation to new frontiers Biochim Biophys Acta 1824 2012 68 88
80. G. Murphy, R. Ward, J. Gavrilovic, S. Atkinson Physiological mechanisms for metalloproteinase activation Matrix Suppl 1 1992 224 230
81. H. Kobayashi, H. Ohi, M. Sugimura, H. Shinohara, T. Fujii, T. Terao Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B Cancer Res 52 1992 3610 3614
82. C.F. Singer, D. Gschwantler-Kaulich, A. Fink-Retter, C. Haas, G. Hudelist, K. Czerwenka, E. Kubista Differential gene expression profile in breast cancer-derived stromal fibroblasts Breast Cancer Res Treat 110 2008 273 281
83. J. Dennemarker, T. Lohmuller, J. Mayerle, M. Tacke, M.M. Lerch, L.M. Coussens, C. Peters, T. Reinheckel Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis Oncogene 29 2010 1611 1621
84. Y. Yasuda, Z. Li, D. Greenbaum, M. Bogyo, E. Weber, D. Bromme Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages J Biol Chem 279 2004 36761 36770
85. U. Rodeck, T. Nishiyama, A. Mauviel Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells Cancer Res 59 1999 547 550
86. C. Berking, R. Takemoto, H. Schaider, L. Showe, K. Satyamoorthy, P. Robbins, M. Herlyn Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling Cancer Res 61 2001 8306 8316
87. D. Javelaud, V.I. Alexaki, A. Mauviel Transforming growth factor-beta in cutaneous melanoma Pigment Cell Melanoma Res 21 2008 123 132
88. G. Jenkins The role of proteases in transforming growth factor-beta activation Int J Biochem Cell Biol 40 2008 1068 1078
89. A. Gopinathan, G.M. Denicola, K.K. Frese, N. Cook, F.A. Karreth, J. Mayerle, M.M. Lerch, T. Reinheckel, D.A. Tuveson Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice Gut 61 2012 877 884
90. E.C. Connolly, J. Freimuth, R.J. Akhurst Complexities of TGF-beta targeted cancer therapy Int J Biol Sci 8 2012 964 978
91. B.T. Elie, V. Gocheva, T. Shree, S.A. Dalrymple, L.J. Holsinger, J.A. Joyce Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model Biochimie 92 2010 1618 1624
92. D.S. Widmer, P.F. Cheng, O.M. Eichhoff, B.C. Belloni, M.C. Zipser, N.C. Schlegel, D. Javelaud, A. Mauviel, R. Dummer, K.S. Hoek Systematic classification of melanoma cells by phenotype-specific gene expression mapping Pigment Cell Melanoma Res 25 2012 343 353